Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Rachel E. Sanborn, Michael J. Pishvaian, Margaret K. Callahan, Amy Weise, Branimir I. Sikic, Osama Rahma, Daniel C. Cho, Naiyer A. Rizvi, Mario Sznol, Jose Lutzky, Julie E. Bauman, Rhonda L. Bitting, Alexander Starodub, Antonio Jimeno, David A. Reardon, Thomas Kaley, Fabio Iwamoto, Joachim M. Baehring, Deepa S. Subramaniam, Jeanny B. Aragon-ChingThomas R. Hawthorne, Tracey Rawls, Michael Yellin, Tibor Keler

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences